Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082914 · ClinicalTrials.gov registry record · Phase 2
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00082914: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00082914 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082914, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with metastatic melanoma or metastatic kidney cancer.
Interventions
- BIOLOGICAL denileukin diftitox
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-03 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
What the finished NCT00082914 record still lists
NCT00082914 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which denileukin diftitox is the first listed.
NCT00082914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00082914 about?
NCT00082914 is a clinical study titled "Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer". RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with metastatic melanoma or metastatic kidney cancer.
What is the current status of trial NCT00082914?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-03. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00082914?
The interventions under investigation include: denileukin diftitox (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082914?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia